News

Celladon and Momentum Research have reported the completion of enrollment of the phase 2 double-blind portion of the Calcium Up-regulation by Percutaneous Administration of Gene Therapy in Cardiac

Catalyst Pharmaceutical has executed a license agreement under which it has acquired exclusive worldwide rights to commercialise GABA aminotransferase inhibitors and derivatives of vigabatrin discovered by Northwestern University.

A study conducted by US-based Merck, demonstrated that in 22,000 patients, nearly three-quarters of patients taking statins still had at least one lipid abnormality. The results from the

PsychoGenics and AstraZeneca have entered into a drug discovery and development agreement to identify compounds that are likely to be useful for the treatment of certain Central Nervous

eClinicalWorks has entered into an agreement with Correctional Medical Services (CMS) to provide its electronic medical records (EMR) solution to correctional facilities affiliated with CMS. CMS facilities using

Orion Health and Cisco have announced the Rhapsody AXP, a new solution to address current challenges in public health reporting and to improve the early detection, tracking and

AstraZeneca has announced results from the phase III head to head trial, PLATO, which demonstrate that ticagrelor (BRILINTA) has achieved greater efficacy in the primary endpoint, reduction of

The Oasis study group has presented initial results of the CURRENT-OASIS 7 clinical trial at the European Society of Cardiology congress in Barcelona. CURRENT-OASIS 7 clinical trial evaluated

Sanofi-aventis’ anti-Xa intravenous anticoagulant otamixaban has reduced by 27 to 42% the odds of the composite primary endpoint of death, myocardial infarction, urgent revascularization or rescue GPIIb/IIIa use